EV Maker Pedals 135% Gains on BTC Treasury Plans

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.

A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.

This free guide includes:

…plus 6 more names with major upside potential.

The early window on these opportunities may be closing — now’s the time to see what’s coming next.

[Get your FREE copy now]

U.S. stocks rose today as stronger-than-expected retail sales and upbeat corporate earnings boosted confidence in the economy, pushing the S&P 500 near record highs.

Walmart (NYSE: WMT) is facing uneven momentum in one of its largest international markets, as its Mexico and Central America division reported a slower-than-expected rebound in consumer demand.

Despite solid sales growth driven by value-focused formats, profit performance fell short of expectations, raising fresh questions about how quickly discretionary spending is returning across Latin America.

The softness in Mexico serves as a reminder that the global retail recovery remains patchy.

While the U.S. market has seen consistent results from grocery and essentials, Walmart’s international performance continues to depend on local conditions and price sensitivity.

Mexico is a strategically important region not just for revenue, but for operational leverage, workforce scale, and long-term store expansion.

Those watching Walmart’s broader execution should note how the company is balancing margin discipline with value-focused positioning abroad.

Even as results fell short in Mexico, Walmart continues to open new stores and lean on formats that prioritize affordability.

That strategy may prove essential if global consumers remain cautious in the second half of the year.

For U.S. investors, this reinforces the importance of tracking international segments alongside domestic strength.

While Mexico remains a core growth market, its performance can significantly influence Walmart’s overall outlook and guide the company's adjustments to pricing, inventory, and capital spending outside the U.S.

Two of the most powerful figures in America are clashing—and it’s not just political drama.

Markets are on edge. Volatility is rising. And your retirement savings could be caught in the crossfire.

But in every crisis, there’s one asset that consistently holds its value—and often rises when everything else falls.

This free guide shows how to use a tax-free, IRS-approved method to protect your wealth now.

[Get Your Free Wealth Protection Guide]

The next financial shock could come without warning. Make sure you’re ready.

Pfizer (NYSE: PFE) is launching a direct-sales program for Eliquis, one of its top-selling drugs, in a shift that sidesteps traditional pharmacy benefit managers and aims to simplify pricing for self-pay and underinsured patients.

Starting in September, eligible patients will be able to order the blood thinner directly through a company-supported program at a substantial discount from the standard list price.

The move comes as Washington intensifies pressure on the pharmaceutical industry to reduce drug costs.

Pfizer’s new strategy reflects a proactive attempt to adapt, offering clearer pricing and reducing third-party markups while maintaining control over how its products are accessed in the U.S. market.

For investors, this marks a notable shift in how Pfizer is preparing for future pricing scrutiny.

With federal reforms, such as Medicare price negotiations, set to reshape U.S. drug economics, Pfizer is signaling that it will not wait for policies to dictate its terms.

Instead, it is actively redefining how high-demand therapies like Eliquis reach the market. Those watching Pfizer’s revenue durability should see this as more than a pricing update.

Direct-to-patient distribution, if scaled, could protect volume, foster goodwill, and enhance visibility into patient behavior, particularly for drugs facing reimbursement uncertainty.

It also allows Pfizer to test a distribution model that could be expanded across other therapeutic areas.

The timing matters too.

With election-year policy threats building and broader access programs gaining ground, Pfizer’s pivot may influence how drugmakers defend core franchises under tighter regulation.

A quiet rule change just gave big banks the green light to treat one physical asset like cold, hard cash.

It’s not stocks. And it’s definitely not dollars.

One economist even called it “the only money banks trust.”

Meanwhile, most Americans are still stuck in risky paper assets.

But there’s a tax-free, penalty-free way to catch up—if you move fast.

Our FREE Wealth Protection Guide breaks it all down.

[Access the guide here before it’s too late]

When insiders buy their stock, it’s usually not for optics. They already have equity, control, and insight into what’s coming.

So when two senior figures at UnitedHealth Group and Middleby spent a combined $118 million of their own money on shares this spring, investors took notice.

These aren’t random board members quietly building a stake. One has just returned to the CEO seat of a Fortune 10 company.

The other is pushing a spin-off at an industrial firm that has been lagging for years. The question now is whether the market has caught up to what they’re already betting on.

UnitedHealth Group (NYSE: UNH), Back Under Familiar Leadership

Stephen Hemsley returned to the top of UnitedHealth on May 13 and had already bought $25 million worth of shares.

That move didn’t come from a place of posturing.

Hemsley was CEO during the company’s 11-year run, which delivered a 360 percent return that was nearly triple the S&P 500's over the same stretch.

He’s not just running the business again. He chairs the board, too, meaning he’s directly overseeing his performance. In short, this is a bet on execution, not potential.

The stock has been pummeled this year.

A cybersecurity breach, leadership shuffle, and regulatory scrutiny have driven UNH's stock price down by more than 40 percent year-to-date.

Yet that same decline has pulled the P/E to just 12.11, with a dividend yield of 3.06 percent.

Analysts have set a $394 price target, implying 36 percent upside from current levels. For those considering a position, Hemsley’s move adds conviction.

Insider buying at this scale, especially from someone with this track record, doesn’t happen without a strong thesis behind it.

Middleby (NASDAQ: MIDD), Quiet Influence, Bold Moves

Edward Garden isn’t a household name, but he’s making waves at Middleby. Between May 9 and May 21, the director bought more than $93 million worth of stock.

Garden’s investment firm now owns 6 percent of the company, and he’s wasting no time flexing that influence.

On the same day Garden was appointed to the board, Middleby announced it would spin off its food processing segment.

That realignment points to a renewed focus on commercial foodservice, its core business.

Investors haven’t yet rewarded the strategy. Shares are down 12 percent since the announcement.

But the company remains a key supplier to major restaurant brands and trades at a modest P/E of 18.17.

The average analyst price target is $168, representing upside from its current level of $145.

For long-term shareholders, Garden’s purchases suggest Middleby’s next chapter may be shaped by someone with both capital and a clear plan.

That combination often precedes change.

Insiders Are Acting Before Headlines Catch Up

Insider trades don’t guarantee returns. But when major figures take large stakes at transitional moments, it’s worth paying attention.

A proven leader is leading UnitedHealth. Middleby is realigning its strategy with backing from an activist investor’s capital.

The buy signals are clear. The only question is, who’s paying attention?

👉 Click here to get our closing report to your cell for free!

Volcon Inc [VLCN] $21.72 (+135.57%)

Volcon shares skyrocketed as the EV maker announced plans to allocate over $500 million from a private stock sale toward building a Bitcoin treasury, mirroring MicroStrategy's crypto strategy.

Draganfly Inc [DPRO] $7.22 (+34.40%)

Draganfly jumped after the U.S. Department of Defense selected its Commander3 XL drone for advanced reconnaissance, while H.C. Wainwright raised its price target.

Pagaya Technologies Ltd [PGY] $29.47 (+25.24%)

Pagaya Technologies rose on strong preliminary Q2 results, with revenue, network volume, and GAAP net income all expected to beat prior guidance.

Pitanium Limited [PTNM] $6.61 (-50.71%)

Shares of Pitanium dropped after trading was halted due to extreme volatility, prompting investor uncertainty following a rapid run-up since its recent listing.

LQR House Inc [YHC] $6.57 (-38.77%)

LQR House sank after a lawsuit filed by Kingbird Ventures called for an asset freeze and court-appointed oversight, overshadowing recent bullish sentiment from a strategic crypto pivot.

GrabAGun Digital Holdings Inc [PEW] $10.19 (-22.37%)

GrabAGun shares fell on debut due to skepticism around its debt-heavy balance sheet and political risk from Trump Jr. backing.

As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.

I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.

Here’s what makes this guide indispensable:

This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.

[Get Your Free Guide Now]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.